Who founded Pharmatrophix?

Pharmatrophix was founded by Frank M. Longo.

Who are Pharmatrophix's investors?

Pharmatrophix's investors include Dolby Family Ventures.

How much funding has Pharmatrophix raised?

Pharmatrophix has disclosed $10.3M raised across 1 round.

Where is Pharmatrophix headquartered?

Pharmatrophix is headquartered in Raleigh, US.

Pharmatrophix

Raleigh, US · Delaware corporation · 1 known investors

Find your way into Pharmatrophix

85 people in our graph share verified history with the Pharmatrophix team — schools, employers, funds. One of them is your warm intro.

Jamie Montgomeryunlockedknows Frank M. Longo · together at UC San Diego (overlapped)

×4knows the team · via UC San Diego

×5knows the team · via University of California, San Francisco

×2knows the team · via University of North Carolina at Chapel Hill

Pharmatrophix is developing a small-molecule drug for Alzheimer's disease that acts upstream of amyloid, with Phase 2a trial imaging showing dose-dependent preservation of whole-brain connectivity. The company works in neurodegenerative disease drug development.

Biotech Healthtech

Founders & leadership

Frank M. Longo inCo-FounderFrank M. Longo is a neurologist and neuroscientist with an MD and PhD in Neuroscience from the University of California, San Diego, and completed neurology residency and neurobiology fellowship at UCSF. He held leadership roles including Chair of Neurology at the University of North Carolina–Chapel Hill and Chair of the Department of Neurology and Neurological Sciences at Stanford Medicine until 2023, where his research has focused on neurodegenerative disease prevention and therapeutics.

Anne C. LongoinSenior Advisor

Board

Robert SimsBoard director

Investors · 1

Dolby Family VenturesreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$10.3M disclosed across 1 round · 2014

▶$10.3MraisedNov 2015 · 15 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Anne C. LongoExecutive Officer
Robert SimsDirector
Frank M. LongoDirector

Offering amount: $10.3M
Amount sold: $10.3M
First sale: Jun 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

ADvantage Therapeutics7 shared keywords

Companies competing with Pharmatrophix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Pharmatrophix do?: Pharmatrophix is developing a small-molecule drug for Alzheimer's disease that acts upstream of amyloid, with Phase 2a trial imaging showing dose-dependent preservation of whole-brain connectivity. The company works in neurodegenerative disease drug development.
Who founded Pharmatrophix?: Pharmatrophix was founded by Frank M. Longo.
Who are Pharmatrophix's investors?: Pharmatrophix's investors include Dolby Family Ventures.
How much funding has Pharmatrophix raised?: Pharmatrophix has disclosed $10.3M raised across 1 round.
Where is Pharmatrophix headquartered?: Pharmatrophix is headquartered in Raleigh, US.